{"id":125206,"date":"2021-10-26T10:36:09","date_gmt":"2021-10-26T14:36:09","guid":{"rendered":"https:\/\/44.250.171.167\/?p=125206"},"modified":"2021-10-26T14:02:40","modified_gmt":"2021-10-26T18:02:40","slug":"how-did-cipla-perform-in-q2-2022","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/how-did-cipla-perform-in-q2-2022\/","title":{"rendered":"How Cipla performed in Q2 2022"},"content":{"rendered":"\n<p>The pharma giant Cipla <a href=\"https:\/\/44.250.171.167\/symbol\/cipla\/\">(NSE: CIPL)<\/a> reported its second-quarter 20223 earnings results on Tuesday after market hours.<\/p>\n\n\n\n<p>The total revenue increased by 10.3% to \u20b95,486 crores compared to \u20b94,972 crores in the previous year of the same quarter.<\/p>\n\n\n\n<p>The company had a total net profit of \u20b9711 crores or \u20b98.80 per share compared to \u20b9665 crores or \u20b98.24 per share in the previous year.<\/p>\n\n\n\n<p>Cipla&#8217;s Ebitda rose 4% YoY to \u20b91,226 crores while Ebitda margin came in at 22.2%,<\/p>\n\n\n\n<p>&#8220;In India, we continue to drive strong performance led by sustained volume traction despite a high FY21 base. Our collaboration with Eli Lily for their diabetes products helps us further strengthen our endeavour of creating access to innovative medicines in line with the One-India strategy,&#8221; said Umang Vohra, MD and Global CEO, Cipla.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The pharma giant Cipla (NSE: CIPL) reported its second-quarter 20223 earnings results on Tuesday after market hours. The total revenue increased by 10.3% to \u20b95,486 crores compared to \u20b94,972 crores in the previous year of the same quarter. The company had a total net profit of \u20b9711 crores or \u20b98.80 per share compared to \u20b9665 [&hellip;]<\/p>\n","protected":false},"author":83,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392,5747,12],"tags":[9191,9138,1408,1115],"class_list":["post-125206","post","type-post","status-publish","format-standard","hentry","category-earnings","category-healthcare-stocks","category-other-industries","tag-medical-distribution","tag-pharma","tag-pharma-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":126049,"url":"https:\/\/alphastreet.com\/india\/infographic-how-cipla-performed-in-q2-2022\/","url_meta":{"origin":125206,"position":0},"title":"Infographic: How Cipla performed in Q2 2022","author":"Nishad","date":"December 6, 2021","format":false,"excerpt":"Cipla Limited(NSE: CIPLA) posted its second-quarter 2022 results. The company posted consolidated revenue of \u20b95,580 crores with a growth of 9% year on year. Cipla had a net profit of \u20b9709 crores or \u20b98.80 per share compared to \u20b9659 crores or \u20b98.24 per share in the same quarter of the\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/CiplaQ222.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/CiplaQ222.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/CiplaQ222.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/CiplaQ222.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/CiplaQ222.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":139207,"url":"https:\/\/alphastreet.com\/india\/infographic-cipla-ltd-nse-cipla-q3-fy23-results-total-income-falls-0-45-qoq\/","url_meta":{"origin":125206,"position":1},"title":"Infographic Cipla Ltd.(NSE: CIPLA) | Q3 FY23 Results | Total Income falls -0.45% qoq","author":"Divyansh_Kasana","date":"January 25, 2023","format":false,"excerpt":"Cipla Limited (NSE: CIPLA) is an Indian multinational pharmaceutical and biopharmaceutical company. Founded in 1935, Cipla primarily develops and sells generic and over-the-counter drugs, active pharmaceutical ingredients, and biopharmaceuticals. The company has operations in over 80 countries, with a focus on the developing world. Cipla is known for its affordable\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/91871a78-5c9c-4023-98bc-ced0a2b4bc5b.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/91871a78-5c9c-4023-98bc-ced0a2b4bc5b.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/91871a78-5c9c-4023-98bc-ced0a2b4bc5b.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/91871a78-5c9c-4023-98bc-ced0a2b4bc5b.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/91871a78-5c9c-4023-98bc-ced0a2b4bc5b.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/91871a78-5c9c-4023-98bc-ced0a2b4bc5b.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":165582,"url":"https:\/\/alphastreet.com\/india\/cipla-ltd-q2fy25-13-rise-in-profits\/","url_meta":{"origin":125206,"position":2},"title":"Cipla Ltd Q2FY25; 13% rise in Profits","author":"Divyansh_Kasana","date":"November 13, 2024","format":false,"excerpt":"Cipla is engaged in the Business of Pharmaceuticals.(Source : 202003 Annual Report Page No:157) Financial Results: Cipla Ltd reported Revenues for Q2FY25 of \u20b97,051.00 Crores up from \u20b96,678.00 Crore year on year, a rise of 5.59%. Total Expenses for Q2FY25 of \u20b95,452.00 Crores up from \u20b95,260.00 Crores year on year,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/DT-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/DT-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/DT-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/DT-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/DT-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/DT-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":167458,"url":"https:\/\/alphastreet.com\/india\/cipla-ltd-q3fy25-47-rise-in-profits\/","url_meta":{"origin":125206,"position":3},"title":"Cipla Ltd Q3FY25; 47% rise in Profits","author":"Divyansh_Kasana","date":"March 19, 2025","format":false,"excerpt":"Cipla is engaged in the Business of Pharmaceuticals.(Source : 202003 Annual Report Page No:157) Financial Results: Cipla Ltd reported Revenues for Q3FY25 of \u20b97,073.00 Crores up from \u20b96,604.00 Crore year on year, a rise of 7.1%. Total Expenses for Q3FY25 of \u20b95,379.00 Crores up from \u20b95,119.00 Crores year on year,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/U-10.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/U-10.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/U-10.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/U-10.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/U-10.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/03\/U-10.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168941,"url":"https:\/\/alphastreet.com\/india\/cipla-ltd-q4fy25-30-rise-in-profits-2\/","url_meta":{"origin":125206,"position":4},"title":"Cipla Ltd Q4FY25; 30% rise in Profits","author":"Divyansh_Kasana","date":"June 30, 2025","format":false,"excerpt":"Cipla is engaged in the Business of Pharmaceuticals.(Source : 202003 Annual Report Page No:157) Financial Results: Cipla Ltd reported Revenues for Q4FY25 of \u20b96,730.00 Crores up from \u20b96,163.00 Crore year on year, a rise of 9.2%. Total Expenses for Q4FY25 of \u20b95,515.00 Crores up from \u20b95,153.00 Crores year on year,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-19.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-19.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-19.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-19.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-19.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-19.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":150055,"url":"https:\/\/alphastreet.com\/india\/cipla-ltd-q1fy24-41-rise-in-profits\/","url_meta":{"origin":125206,"position":5},"title":"Cipla Ltd Q1FY24; 41% rise in Profits.","author":"Divyansh_Kasana","date":"July 26, 2023","format":false,"excerpt":"Cipla is engaged in the Business of Pharmaceuticals. Financial Results: Cipla Ltd reported Revenues for Q1FY24 of \u20b96,329.00 Crores up from \u20b95,375.00 Crore year on year, a rise of 17.75%. Total Expenses for Q1FY24 of \u20b95,090.00 Crores up from \u20b94,504.00 Crores year on year, a rise of 13.01%. Consolidated Net\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-269.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-269.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-269.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-269.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-269.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-269.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/125206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/83"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=125206"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/125206\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=125206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=125206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=125206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}